<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02044991</url>
  </required_header>
  <id_info>
    <org_study_id>205418</org_study_id>
    <nct_id>NCT02044991</nct_id>
  </id_info>
  <brief_title>Ultrasound Guided Posterior Sacroiliac Ligament Corticosteroid Injection in Pregnancy-Related Pelvic Girdle Pain</brief_title>
  <official_title>The Efficacy of Ultrasound Guided Posterior Sacroiliac Ligament Corticosteroid Injection in Pregnancy-Related Pelvic Girdle Pain: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Loyola University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Academy of Physical Medicine and Rehabilitation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Loyola University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if pelvic girdle pain can be more effectively treated
      with the use of injectable anti-inflammatory medication plus physical therapy compared with
      physical therapy and a saline injection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pelvic girdle pain (PGP) in pregnancy is common with prevalence estimates of 45%.1 It is
      defined as pain experienced between the posterior iliac crest and the gluteal fold,
      particularly in the region of the sacroiliac joint.2 Pain may radiate in the posterior thigh
      and can also occur in conjunction with/or separately in the symphysis. In PGP, the endurance
      capacity for standing, walking and sitting is diminished. The diagnosis of PGP can be reached
      after exclusion of lumbar causes and must be reproducible by specific clinical tests. While
      various pain mechanisms including mechanical, hormonal, inflammatory, and neural have been
      proposed in the development of PGP, the etiology and pathogenesis is poorly understood. It is
      possible that musculoskeletal changes influenced by hormonal (Relaxin) elevation in pregnancy
      predispose pregnant women to acute musculoskeletal injury presenting clinically as PGP. An
      inflammatory response in other acute musculoskeletal injuries has been well described3 and
      may also occur in pregnancy related PGP particularly given the musculoskeletal vulnerability
      during this time. Though PGP is common in pregnancy, no study to date has investigated the
      efficacy of anti-inflammatory treatment in pregnancy related PGP in order to better establish
      the contribution of inflammation in the etiology of pregnancy related PGP.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study was halted prematurely due to poor recruitment
  </why_stopped>
  <start_date type="Actual">October 24, 2013</start_date>
  <completion_date type="Actual">February 22, 2017</completion_date>
  <primary_completion_date type="Actual">February 22, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants are assigned to receive either an injection of methylprednisolone acetate plus lidocaine or to receive an injection of saline with lidocaine using a randomized block design with a 1:1 allocation.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Pain</measure>
    <time_frame>8 weeks</time_frame>
    <description>Pain is measured using the Pain Numeric Rating Scale (NRS), which ranges from 0 to 10 with higher scores indicating greater pain. This measure is recorded at baseline (0 weeks) and 8 weeks. The change in pain between these two time points (i.e., the difference score) is compared between the two groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pelvic Functioning</measure>
    <time_frame>8 weeks</time_frame>
    <description>Pelvic functioning is measured at baseline (0 weeks) and week 8 using the Pelvic Girdle Questionnaire (PGQ), which ranges from 0 to 100 points with higher scores revealing greater pelvic girdle pain. The change in pelvic functioning between these two time points (i.e., the difference score) is compared between the two groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disability</measure>
    <time_frame>8 weeks</time_frame>
    <description>Disability is measured at baseline (0 weeks) and week 8 using the Oswestry Disability Index (ODI), which is a measure of low back pain that ranges from 0 points to 100 with higher scores indicating greater disability. The change in disability between these two time points (i.e., the difference score) is compared between the two groups.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Pelvic Girdle Pain</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants randomized to this arm will receive a corticosteroid. This is 40mg of a non-fluorinated injectable glucocorticoid, methylprednisolone acetate (1cc) combined with 1cc of 1% Lidocaine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participant's randomized to this condition will receive a placebo injection once weekly</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Corticosteroid</intervention_name>
    <description>40mg of a non-fluorinated injectable glucocorticoid, methylprednisolone acetate (1cc) combined with 1cc of 1% Lidocaine</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Medrol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Injection</intervention_name>
    <description>A placebo injection</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women who are not doing other therapies for pain (physical therapy, chiropractic
             management, pool)

          -  Women between age 21 and 50 who plan to deliver at Loyola or Gottlieb

          -  Pain Numeric Rating Scale (NRS) on average of greater than or equal to 5/10 at Visit 1

          -  Pain must be between the upper level of the iliac crests and the gluteal folds in
             conjunction with or separately from pain in the pubic symphysis and influenced by
             position and locomotion

          -  2/4 positive physical examination tests on the symptomatic side including the P4 test,
             the LDL test, pubic symphysis palpation and the acute straight leg rise (ASLR)

        Exclusion Criteria:

          -  Women presenting with PGP in the first or third trimester (&lt;13 weeks gestation or &gt;28
             weeks gestation)

          -  Women with pubic symphysis (anterior) pain alone

          -  Women who do not plan to deliver a baby at Loyola or Gottlieb

          -  Pain above the upper level of the iliac crest

          -  History of lumbar or pelvic fracture, neoplasm, inflammatory disease, active
             urogenital infection or active gastrointestinal illness, current physical therapy or
             other therapies for PGP, or previous surgery of the lumbar spine, pelvic girdle, hip
             joint or femur

          -  History or signs of radiculopathy or other systemic neurologic disease

          -  Women with diabetes or gestational diabetes
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Colleen Fitzgerald, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Loyola Univ Med Cntr-</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Loyola University Health System</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Wu WH, Meijer OG, Uegaki K, Mens JM, van Dieën JH, Wuisman PI, Ostgaard HC. Pregnancy-related pelvic girdle pain (PPP), I: Terminology, clinical presentation, and prevalence. Eur Spine J. 2004 Nov;13(7):575-89. Epub 2004 Aug 27. Review.</citation>
    <PMID>15338362</PMID>
  </reference>
  <reference>
    <citation>Ekman EF, Koman LA. Acute pain following musculoskeletal injuries and orthopaedic surgery: mechanisms and management. Instr Course Lect. 2005;54:21-33. Review.</citation>
    <PMID>15948432</PMID>
  </reference>
  <reference>
    <citation>Kristiansson P, Svärdsudd K, von Schoultz B. Serum relaxin, symphyseal pain, and back pain during pregnancy. Am J Obstet Gynecol. 1996 Nov;175(5):1342-7.</citation>
    <PMID>8942512</PMID>
  </reference>
  <reference>
    <citation>Stapleton DB, MacLennan AH, Kristiansson P. The prevalence of recalled low back pain during and after pregnancy: a South Australian population survey. Aust N Z J Obstet Gynaecol. 2002 Nov;42(5):482-5.</citation>
    <PMID>12495090</PMID>
  </reference>
  <reference>
    <citation>Gutke A, Josefsson A, Oberg B. Pelvic girdle pain and lumbar pain in relation to postpartum depressive symptoms. Spine (Phila Pa 1976). 2007 Jun 1;32(13):1430-6.</citation>
    <PMID>17545912</PMID>
  </reference>
  <reference>
    <citation>Brynhildsen J, Hansson A, Persson A, Hammar M. Follow-up of patients with low back pain during pregnancy. Obstet Gynecol. 1998 Feb;91(2):182-6.</citation>
    <PMID>9469272</PMID>
  </reference>
  <reference>
    <citation>Stuge B, Hilde G, Vøllestad N. Physical therapy for pregnancy-related low back and pelvic pain: a systematic review. Acta Obstet Gynecol Scand. 2003 Nov;82(11):983-90. Review.</citation>
    <PMID>14616270</PMID>
  </reference>
  <reference>
    <citation>Stuge B, Laerum E, Kirkesola G, Vøllestad N. The efficacy of a treatment program focusing on specific stabilizing exercises for pelvic girdle pain after pregnancy: a randomized controlled trial. Spine (Phila Pa 1976). 2004 Feb 15;29(4):351-9.</citation>
    <PMID>15094530</PMID>
  </reference>
  <reference>
    <citation>Albert H, Godskesen M, Westergaard J. Prognosis in four syndromes of pregnancy-related pelvic pain. Acta Obstet Gynecol Scand. 2001 Jun;80(6):505-10.</citation>
    <PMID>11380285</PMID>
  </reference>
  <reference>
    <citation>Stuge B, Veierød MB, Laerum E, Vøllestad N. The efficacy of a treatment program focusing on specific stabilizing exercises for pelvic girdle pain after pregnancy: a two-year follow-up of a randomized clinical trial. Spine (Phila Pa 1976). 2004 May 15;29(10):E197-203.</citation>
    <PMID>15131454</PMID>
  </reference>
  <reference>
    <citation>Elden H, Fagevik-Olsen M, Ostgaard HC, Stener-Victorin E, Hagberg H. Acupuncture as an adjunct to standard treatment for pelvic girdle pain in pregnant women: randomised double-blinded controlled trial comparing acupuncture with non-penetrating sham acupuncture. BJOG. 2008 Dec;115(13):1655-68. doi: 10.1111/j.1471-0528.2008.01904.x. Epub 2008 Oct 15.</citation>
    <PMID>18947338</PMID>
  </reference>
  <reference>
    <citation>Haugland KS, Rasmussen S, Daltveit AK. Group intervention for women with pelvic girdle pain in pregnancy. A randomized controlled trial. Acta Obstet Gynecol Scand. 2006;85(11):1320-6.</citation>
    <PMID>17091411</PMID>
  </reference>
  <reference>
    <citation>Bastiaenen CH, de Bie RA, Wolters PM, Vlaeyen JW, Leffers P, Stelma F, Bastiaanssen JM, Essed GG, van den Brandt PA. Effectiveness of a tailor-made intervention for pregnancy-related pelvic girdle and/or low back pain after delivery: short-term results of a randomized clinical trial [ISRCTN08477490]. BMC Musculoskelet Disord. 2006 Feb 27;7:19.</citation>
    <PMID>16504165</PMID>
  </reference>
  <reference>
    <citation>Lin J, Fessell DP, Jacobson JA, Weadock WJ, Hayes CW. An illustrated tutorial of musculoskeletal sonography: part I, introduction and general principles. AJR Am J Roentgenol. 2000 Sep;175(3):637-45.</citation>
    <PMID>10954443</PMID>
  </reference>
  <reference>
    <citation>Le Goff B, Berthelot JM, Maugars Y. Ultrasound assessment of the posterior sacroiliac ligaments. Clin Exp Rheumatol. 2011 Nov-Dec;29(6):1014-7. Epub 2011 Dec 22.</citation>
    <PMID>22206650</PMID>
  </reference>
  <reference>
    <citation>Pekkafahli MZ, Kiralp MZ, Başekim CC, Silit E, Mutlu H, Oztürk E, Kizilkaya E, Dursun H. Sacroiliac joint injections performed with sonographic guidance. J Ultrasound Med. 2003 Jun;22(6):553-9.</citation>
    <PMID>12795552</PMID>
  </reference>
  <reference>
    <citation>Schull WJ, Otake M. Cognitive function and prenatal exposure to ionizing radiation. Teratology. 1999 Apr;59(4):222-6. Review.</citation>
    <PMID>10331523</PMID>
  </reference>
  <reference>
    <citation>Ruiz-Irastorza G, Khamashta MA. Managing lupus patients during pregnancy. Best Pract Res Clin Rheumatol. 2009 Aug;23(4):575-82. doi: 10.1016/j.berh.2009.04.004.</citation>
    <PMID>19591786</PMID>
  </reference>
  <reference>
    <citation>Baer AN, Witter FR, Petri M. Lupus and pregnancy. Obstet Gynecol Surv. 2011 Oct;66(10):639-53. doi: 10.1097/OGX.0b013e318239e1ee. Review.</citation>
    <PMID>22112525</PMID>
  </reference>
  <reference>
    <citation>Roberts D, Dalziel S. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev. 2006 Jul 19;(3):CD004454. Review. Update in: Cochrane Database Syst Rev. 2017 Mar 21;3:CD004454.</citation>
    <PMID>16856047</PMID>
  </reference>
  <reference>
    <citation>Ostensen M, Ramsey-Goldman R. Treatment of inflammatory rheumatic disorders in pregnancy: what are the safest treatment options? Drug Saf. 1998 Nov;19(5):389-410. Review.</citation>
    <PMID>9825952</PMID>
  </reference>
  <reference>
    <citation>Cole BJ, Schumacher HR Jr. Injectable corticosteroids in modern practice. J Am Acad Orthop Surg. 2005 Jan-Feb;13(1):37-46. Review.</citation>
    <PMID>15712981</PMID>
  </reference>
  <reference>
    <citation>Kumar N, Newman RJ. Complications of intra- and peri-articular steroid injections. Br J Gen Pract. 1999 Jun;49(443):465-6.</citation>
    <PMID>10562748</PMID>
  </reference>
  <reference>
    <citation>Slotkoff AT, Katz P. Approach to the patient with rheumatoid arthritis. Adv Intern Med. 1994;39:197-240. Review.</citation>
    <PMID>7908157</PMID>
  </reference>
  <reference>
    <citation>Plastaras CT, Joshi AB, Garvan C, Chimes GP, Smeal W, Rittenberg J, Lento P, Stanos S, Fitzgerald C. Adverse events associated with fluoroscopically guided sacroiliac joint injections. PM R. 2012 Jul;4(7):473-8. doi: 10.1016/j.pmrj.2012.02.001. Epub 2012 Apr 28.</citation>
    <PMID>22543036</PMID>
  </reference>
  <reference>
    <citation>Jacobs JW, Michels-van Amelsfort JM. How to perform local soft-tissue glucocorticoid injections? Best Pract Res Clin Rheumatol. 2013 Apr;27(2):171-94. doi: 10.1016/j.berh.2013.03.003. Review.</citation>
    <PMID>23731930</PMID>
  </reference>
  <reference>
    <citation>Elimian A, Goodman JR, Knudtson E, Wagner A, Wilson P, Williams M. Local anesthesia and pain perception during amniocentesis: a randomized double blind placebo-controlled trial. Prenat Diagn. 2013 Dec;33(12):1158-61. doi: 10.1002/pd.4214. Epub 2013 Sep 1.</citation>
    <PMID>23939867</PMID>
  </reference>
  <reference>
    <citation>Edelman A, Nichols MD, Leclair C, Astley S, Shy K, Jensen JT. Intrauterine lidocaine infusion for pain management in first-trimester abortions. Obstet Gynecol. 2004 Jun;103(6):1267-72.</citation>
    <PMID>15172863</PMID>
  </reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 17, 2014</study_first_submitted>
  <study_first_submitted_qc>January 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2014</study_first_posted>
  <results_first_submitted>April 3, 2017</results_first_submitted>
  <results_first_submitted_qc>April 3, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 12, 2017</results_first_posted>
  <last_update_submitted>August 4, 2017</last_update_submitted>
  <last_update_submitted_qc>August 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Loyola University</investigator_affiliation>
    <investigator_full_name>Colleen Fitzgerald</investigator_full_name>
    <investigator_title>M.D., Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Sciatica</keyword>
  <keyword>Pelvic girdle pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pelvic Girdle Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no plan to share individual participant data</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment for this trial began in May 2015 and ended in May 2016 (12 months). The trial was terminated in February 2017 due to poor recruitment</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment</title>
          <description>Participants randomized to this arm receive an injectable anti-inflammatory medication (methylprednisolone acetate) plus lidocaine</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Participant's randomized to this condition receive a saline injection with lidocaine.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The baseline analysis population comprises all participants who signed an informed consent document to participate in the trial.</population>
      <group_list>
        <group group_id="B1">
          <title>Treatment</title>
          <description>Participants randomized to this arm receive an injectable anti-inflammatory medication (methylprednisolone acetate) plus lidocaine</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Participant's randomized to this condition receive a saline injection with lidocaine.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="2"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Pain</title>
        <description>Pain is measured using the Pain Numeric Rating Scale (NRS), which ranges from 0 to 10 with higher scores indicating greater pain. This measure is recorded at baseline (0 weeks) and 8 weeks. The change in pain between these two time points (i.e., the difference score) is compared between the two groups.</description>
        <time_frame>8 weeks</time_frame>
        <population>The trial was prematurely terminated in February 2017 due to poor recruitment. No statistical analysis is conducted.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Participants randomized to this arm receive an injectable anti-inflammatory medication (methylprednisolone acetate) plus lidocaine</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participant's randomized to this condition receive a saline injection with lidocaine.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Pain</title>
          <description>Pain is measured using the Pain Numeric Rating Scale (NRS), which ranges from 0 to 10 with higher scores indicating greater pain. This measure is recorded at baseline (0 weeks) and 8 weeks. The change in pain between these two time points (i.e., the difference score) is compared between the two groups.</description>
          <population>The trial was prematurely terminated in February 2017 due to poor recruitment. No statistical analysis is conducted.</population>
          <units>change score on the NRS pain scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3" lower_limit="-5" upper_limit="-1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pelvic Functioning</title>
        <description>Pelvic functioning is measured at baseline (0 weeks) and week 8 using the Pelvic Girdle Questionnaire (PGQ), which ranges from 0 to 100 points with higher scores revealing greater pelvic girdle pain. The change in pelvic functioning between these two time points (i.e., the difference score) is compared between the two groups.</description>
        <time_frame>8 weeks</time_frame>
        <population>The trial was prematurely terminated in February 2017 due to poor recruitment. No statistical analysis is conducted.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Participants randomized to this arm receive an injectable anti-inflammatory medication (methylprednisolone acetate) plus lidocaine</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participant's randomized to this condition receive a saline injection with lidocaine.</description>
          </group>
        </group_list>
        <measure>
          <title>Pelvic Functioning</title>
          <description>Pelvic functioning is measured at baseline (0 weeks) and week 8 using the Pelvic Girdle Questionnaire (PGQ), which ranges from 0 to 100 points with higher scores revealing greater pelvic girdle pain. The change in pelvic functioning between these two time points (i.e., the difference score) is compared between the two groups.</description>
          <population>The trial was prematurely terminated in February 2017 due to poor recruitment. No statistical analysis is conducted.</population>
          <units>change score on the PGQ scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-35.5" lower_limit="-75" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disability</title>
        <description>Disability is measured at baseline (0 weeks) and week 8 using the Oswestry Disability Index (ODI), which is a measure of low back pain that ranges from 0 points to 100 with higher scores indicating greater disability. The change in disability between these two time points (i.e., the difference score) is compared between the two groups.</description>
        <time_frame>8 weeks</time_frame>
        <population>The trial was prematurely terminated in February 2017 due to poor recruitment. No statistical analysis is conducted.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Participants randomized to this arm receive an injectable anti-inflammatory medication (methylprednisolone acetate) plus lidocaine</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participant's randomized to this condition receive a saline injection with lidocaine.</description>
          </group>
        </group_list>
        <measure>
          <title>Disability</title>
          <description>Disability is measured at baseline (0 weeks) and week 8 using the Oswestry Disability Index (ODI), which is a measure of low back pain that ranges from 0 points to 100 with higher scores indicating greater disability. The change in disability between these two time points (i.e., the difference score) is compared between the two groups.</description>
          <population>The trial was prematurely terminated in February 2017 due to poor recruitment. No statistical analysis is conducted.</population>
          <units>change score on the ODI scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.25" lower_limit="-44.5" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected for 1 year, 7 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment</title>
          <description>Participants randomized to this arm receive an injectable anti-inflammatory medication (methylprednisolone acetate) plus lidocaine</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Participant's randomized to this condition receive a saline injection with lidocaine.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Premature birth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Premature contractions</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The trial was terminated in February 2017 due to poor recruitment</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Colleen Fitzgerald, M.D., M.S.</name_or_title>
      <organization>Loyola University</organization>
      <phone>708-216-2180</phone>
      <email>cfitzgerald@lumc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

